MYHEP ALL

Myhep all is an anti-hepatitis C viral medicine, containing active components known as Sofosbuvir and Velpatasvir available in the strength of 400mg & 100mg respectively.
Velpatasvir is a class of anti-hepatitis C viral drug, called NS5A multiplication complex inhibitors.
This may have combined with other anti-viral agent Sofosbuvir which expels its work by stopping the virus which may causes hepatitis C viral infection from spreading inside the body.
Myhep all tablet is not a curable; it is only used to control the spreading of disease.

MYHEP ALL DRUG INTERACTIONS :

P-gp or BCRP inducers combination with Myhep all causes depletion of plasma concentration of Myhep all leads to decreasing the therapeutic effect of Myhep all.

P-gp or BCRP inhibitors concurrent use with Myhep all tablets leads to increase the exposure of these drugs.

Myhep all is concurrently used with gastric regulators, causes decreasing the plasma concentration of Velpatasvir.

Myhep all combined with amiodarone cause severe life threatening cardiac effects like bradycardia.

Myhep all combined with digoxin, causes increases effect of concentration of digoxin.

Myhep all tablets combined with anti-convulsants causes’ decrease in plasma concentration of Myhep all

Myhep all tablets with herbal product like st.Johns wort causes decreasing the effect of Velpatasvir.

Myhep all tablets combined with HMG CoA reductase inhibitors causes increasing the effedt of concentration of these drugs.

Exposure of hepatitis B viral infection occurs in HBV/HCV co infections Serious symptomatic bradycardia while concomitant with amiodarone Risk of depletion of therapeutic effect occurs due to combination of Myhep all with P-gp inducers or CYP3A4 inducers.

Fetal adverse occurs while concomitant with ribavirin For all these conditions, withhold or discontinue the therapy with Myhep alltablets.